Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland

Partial adherence: a new perspective on health economic assessment in osteoporosis

(2011) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX®

(2010) John A. Kanis et al.   BONE

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

(2010) A. Papaioannou et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

The diagnosis of osteoporosis

(2010) John A. Kanis et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

(2010) B. Jönsson et al.   OSTEOPOROSIS INTERNATIONAL

An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women

(2010) John A. Kanis et al.   Archives of Osteoporosis

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX®

(2009) John A. Kanis et al.   BONE

FRAX® and its applications to clinical practice

(2009) John A. Kanis et al.   BONE

Assessment of fracture risk

(2009) John A. Kanis et al.   EUROPEAN JOURNAL OF RADIOLOGY

Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

(2009) J. Compston et al.   MATURITAS

FRAX® assessment of osteoporotic fracture probability in Switzerland

(2009) K. Lippuner et al.   OSTEOPOROSIS INTERNATIONAL

The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis

(2009) F. Borgström et al.   OSTEOPOROSIS INTERNATIONAL

The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®

(2009) F. Borgström et al.   OSTEOPOROSIS INTERNATIONAL

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

(2009) Johann D. Ringe et al.   RHEUMATOLOGY INTERNATIONAL

A Revised Clinician’s Guide to the Prevention and Treatment of Osteoporosis

(2008) Bess Dawson-Hughes   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Differences in persistence among different weekly oral bisphosphonate medications

(2008) O. Sheehy et al.   OSTEOPOROSIS INTERNATIONAL

Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study

(2008) E. V. McCloskey et al.   OSTEOPOROSIS INTERNATIONAL

Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women

(2008) K. Lippuner et al.   OSTEOPOROSIS INTERNATIONAL

Cost-effective osteoporosis treatment thresholds: the United States perspective

(2008) A. N. A. Tosteson et al.   OSTEOPOROSIS INTERNATIONAL

Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA

(2008) B. Dawson-Hughes et al.   OSTEOPOROSIS INTERNATIONAL

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

The cost-effectiveness of alendronate in the management of osteoporosis

(2007) John A. Kanis et al.   BONE

A reference standard for the description of osteoporosis

(2007) John A. Kanis et al.   BONE